Results 10,801-10,820 of 20,765 for speaker:Alan Kelly
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: I thank the witnesses from both bodies for their honesty in answering our questions, as this is obviously a very emotional topic. I will digress here slightly. There are media reports out today about the drug Entresto. The issues around this particular drug have been talked about for some time now. Seeing as they are here with us today, perhaps the witnesses will clarify the situation...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Some €120 million over five years for all nine?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Ultimately, is this a matter for the Department of Health?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: I asked a very specific question. Ultimately, the NCPE has passed these nine drugs. It would cost €120 million over five years, and I thank Mr. Hennessy for clarifying that. The NCPE has gone through its process and the HSE has gone through its process. The matter is now sitting on the Minister's desk. This is not a political attack and I ask that it not be taken that way. I know...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: That is not acceptable. I asked a specific question and I want an answer.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: That is not acceptable.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: As long as the answer is about that drug and Mr. Hennessy does not name it, that is fine.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Mr. Hennessy still has not answered the question.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Mr. Hennessy has not. Is this a cost-effective drug as recommended by the NCPE? If so, in that scenario, is that unique? Why has it not been funded?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Is Mr. Hennessy saying that every drug recommended by NCPE is cost effective?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Professor Barry does not work for the HSE, so maybe he might elaborate on the questions that I asked, because they do not always have to be answered by the HSE.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Fair enough.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Is this cost effective?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: To tease this out, are the witnesses saying that there would be no cost-saving?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: What about the stake-----
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: I appreciate that, and Mr. Flanagan is not going to be locked in to what he said on that point. I am not going to hang him on that. Has he taken into consideration the saving in acute hospital expenditure because that drug is being used?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Some €25 million?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Does Professor Barry want to comment?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: And it is easy to distinguish.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: It needs nine more.